SAB Biotherapeutics, Inc.

NASDAQ:SABS

Biotechnology

Healthcare
$2.91 -0.53%

-$0.02 today

Market cap
$262.16M
Beta
0.53
P/E (TTM)
3.0
EPS (TTM)
-$0.16
52W Low $1.85High $5.15

Volume 1.75M

Average 0.76M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$48.95M

FY 2025 · Annual

Net Income

$13.27M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue60.88M23.9M2.24M1.32M0
Cost of Revenue1.65M3.29M3.75M4.79M3.08M
Gross Profit59.22M20.61M(1.51M)(3.47M)(3.08M)
Gross Margin97.3%86.2%-67.3%-262.4%—
Research & Development57.18M36.44M16.52M30.16M34.35M
Selling, General & Admin17.09M16.38M23.8M9.28M14.6M
Operating Expenses72.62M49.53M36.57M39.44M45.87M
Depreciation & Amortization1.65M3.29M3.75M4.79M3.08M
EBITDA(15.2M)(15.12M)(38.13M)(28.99M)16.6M
EBITDA Margin-25.0%-63.3%-1703.1%-2192.5%—
Operating Income(13.39M)(28.92M)(38.08M)(42.91M)(48.95M)
Operating Margin-22.0%-121.0%-1700.5%-3244.9%—
Interest Income23.12K71.07K584.97K1.29M1.43M
Interest Expense294.46K301.58K315.28K318.4K240.66K
Other Income / Expenses(3.75M)10.2M(4.12M)8.81M62.23M
Income Before Tax(17.15M)(18.72M)(42.19M)(34.11M)13.27M
Pre-Tax Margin-28.2%-78.3%-1884.5%-2579.0%—
Income Tax Expense025.63K000
Net Income(17.15M)(18.74M)(42.19M)(34.11M)13.27M
Net Margin-28.2%-78.4%-1884.5%-2579.0%—
EPS (Basic)(3.94)(4.31)(7.64)(3.68)0.22
EPS (Diluted)(6.30)(4.31)(7.64)(3.68)(0.79)
Weighted Avg Shares4.35M4.35M5.52M9.26M19.31M
Weighted Avg Shares (Diluted)2.73M4.35M5.52M9.26M61.34M

SABS Earnings Waterfall · TTM

NASDAQ:SABS · Revenue to Net Income

Key Ratios

EPS$-0.86
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.6
P/S Ratio0.0

Analysis

$0 of revenue converted into -$12.8M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.86, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 5, 2026
25-NSE25-NSE filingOct 22, 2026
8-KCurrent reportOct 13, 2026
4Statement of changes in beneficial ownershipSep 18, 2026
424B3424B3 filingAug 21, 2026

How much revenue does SABS generate?

SAB Biotherapeutics, Inc. (SABS) reported $0.00 of revenue in fiscal 2025.

Is SABS profitable?

SAB Biotherapeutics, Inc. (SABS) reported $13.27M of net income.